Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas

Texto completo
Autor(es):
Acar, Vitoria [1] ; Couto Fernandez, Fabio Leite [2] ; Buscariolo, Fabio Fabian [1] ; Novais, Adriana Alonso [3] ; Matheus Pereira, Roseli Aparecida [4] ; Pires de Campos Zuccari, Debora Aparecida [5]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Sao Jose do Rio Preto Med Sch FAMERP, Sao Jose Do Rio Preto, SP - Brazil
[2] Sao Jose do Rio Preto Med Sch FAMERP, Dept Clin Med, Sao Jose Do Rio Preto, SP - Brazil
[3] Sao Jose do Rio Preto Med Sch FAMERP, Canc Mol Res Lab, Sao Jose Do Rio Preto, SP - Brazil
[4] Sao Jose do Rio Preto Med Sch FAMERP, Dept Nursing, Sao Jose Do Rio Preto, SP - Brazil
[5] Sao Jose do Rio Preto Med Sch FAMERP, Dept Mol Biol, Sao Jose Do Rio Preto, SP - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: CLINICAL MEDICINE & RESEARCH; v. 19, n. 4, p. 183-191, DEC 1 2021.
Citações Web of Science: 0
Resumo

Prostate cancer is the second most common neoplasm among men, with a high mortality rate in advanced stages. Poly (ADP-ribose) polymerase (PARP) plays an important role in repair to DNA damage, being associated with resistance to tumor cell death. Conversely, Caspase-3 is a crucial mediator of programmed cell death, being highly expressed in apoptotic cells.The aim of the present study was to characterize the expression of PARP and Caspase-3 by immunohistochemistry in patients with advanced prostate cancer. PARP and Caspase-3 were independently correlated to patients' evolution, in accordance with the classification of prognostic groups.The increase in PARP expression was positively correlated with tumor patients with poor prognosis (P < 0.0001). In contrast, a decrease in Caspase-3 expression was identified in patients with poor prognosis, when compared with prostate cancer patients with good prognosis (P = 0.0007). Numerically, 92.3% of patients previously classified with poor prognosis showed higher PARP expression, while 93.75% of patients previously classified with good prognosis showed higher levels of Caspase-3.We conclude that PARP and Caspase-3 are potential prognostic markers for prostate cancer patients with different prognosis. (AU)

Processo FAPESP: 19/11381-1 - Avaliação imuno-histoquímica de PARP e caspase-3 como marcadores prognósticos em carcinomas de próstata
Beneficiário:Vitoria Acar
Modalidade de apoio: Bolsas no Brasil - Iniciação Científica